You have free access to this content

Value in Health

Cover image for Value in Health

March 2001

Volume 4, Issue 2

Pages 47–195

  1. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      CONTRIBUTED PODIUM PRESENTATIONS (pages 47–65)

      Version of Record online: 28 JUN 2008 | DOI: 10.1046/j.1524-4733.2001.00042.x

  2. Economic Methodology Issues

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      RISK ATTITUDE: ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS (page 47)

      Me Singer, H Beaird and Lan Miller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.004002047.x

    2. You have free access to this content
      THE IMPACT OF HOSPITAL COSTING METHODS ON STATISTICAL POWER IN MULTINATIONAL CLINICAL TRIALS (pages 47–48)

      Sd Reed, Jy Friedman, Jh Malenbaum, A Gnanasakthy and Ka Schulman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-2.x

    1. You have free access to this content
      Contributed Podium Presentations (pages 47–66)

      Version of Record online: 1 MAY 2002 | DOI: 10.1046/j.1524-4733.2001.00201.x

  3. Economic Methodology Issues

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS (page 48)

      Dd McDonnell and Ja Donohue

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-3.x

  4. Medical Device & Diagnostics

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS: IS PEACE OF MIND MORE IMPORTANT THAN SAVING LIVES? (pages 48–49)

      P Cram, S Vijan, Am Wolbrink and Am Fendrick

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-5.x

  5. Economic Methodology Issues

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES? (page 48)

      R Brown, J Hutton and M Nuijten

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-4.x

  6. Medical Device & Diagnostics

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF-ASSESSED HEALTH STATUS RATING (page 49)

      Ab Rodney, H Xiao and T Robertson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-6.x

    2. You have free access to this content
      INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES: HOW IMPORTANT IS IT? (pages 49–50)

      S Subramanian and Bj Justason

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-8.x

    3. You have free access to this content
  7. Quality of Life & Preference-based Measures

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH: AN ANALYSIS OF US SURVEY DATA (pages 50–51)

      Bm Craig and P Kind

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-10.x

    2. You have free access to this content
      DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH? (page 50)

      Y Asada, Nk Stout and P Kind

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-9.x

    3. You have free access to this content
      QUALITY OF LIFE IN PRODUCT LABELING: A REVIEW OF MARKETED DRUG PRODUCTS (page 51)

      T Chopra, Sn Shah, C McLaughlin-Miley and J Hinton

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-11.x

  8. Health Policy

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
  9. Quality of Life & Preference-based Measures

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990–99 (page 51)

      K Zivin and P Neumann

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-12.x

  10. Health Policy

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS (page 52)

      Lm Cooper and Wt Linde-Zwirble

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-14.x

    2. You have free access to this content
      INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS: EVALUATION OF 30 MONTHS OF EXPERIENCE (pages 52–53)

      De Atherly, Sd Sullivan, Ds Fullerton and Ll Sturm

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-15.x

  11. Cancer

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT (pages 53–54)

      Dm Franic and Ds Pathak

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-18.x

    2. You have free access to this content
      UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR) (page 53)

      R Hauser, R Theriault, J Wilson, M Shepherd, K Lawson and J Koeller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-17.x

  12. Health Policy

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
  13. Cancer

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK (pages 54–55)

      N Botwood, J McKendrick, M Aristides, M Lees, N Maniadakis, W Wein and D Stephenson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-20.x

    2. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN+5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK (page 54)

      R Brown, S Sorensen, A Burrell and A Bearne

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-19.x

  14. Cardiovascular Disease

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS? (pages 55–56)

      P Reddy, B Feret, L Kulicki, S Jordan, S Donahue and R Quercia

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-23.x

    2. You have free access to this content
      INDIRECT COMPARISONS OF DRUGS USING META-ANALYSIS: VALIDATION OF RESULTS (page 55)

      Sd Ross, S Klawansky and Ie Allen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-22.x

    3. You have free access to this content
      THE VALUE OF COMPLIANCE: EVIDENCE FROM TWO PATIENT COHORTS (page 55)

      Ka McGuigan, M Sokol, J Yao, J Haynes, Q Qian, J Boscarino and R Epstein

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-21.x

    4. You have free access to this content
      USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION (page 56)

      J Piercy, P James, D Baum and L Kuester

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-24.x

    5. You have free access to this content
      THE COST-EFFECTIVENESS OF LIFETIME FACTOR VIII PROPHYLAXIS IN THE TREATMENT OF SEVERE HEMOPHILIA A (pages 56–57)

      Ra Charles and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-25.x

    6. You have free access to this content
      COST-EFFECTIVENESS OF CARDIOVASCULAR DISEASE (CVD) PREVENTION BY REDUCING POSTPRANDIAL HYPERGLYCEMIA (page 57)

      H Glick, Q Qiao and J Grueger

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-27.x

    7. You have free access to this content
      ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS (page 57)

      Na Risebrough and N Mittmann

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-26.x

    8. You have free access to this content
      WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION (pages 57–58)

      Sr Erickson, Cr McBurney, Em Kline-Rogers, Jv Cooper, Ocm Mani and Ka Eagle

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-28.x

  15. Diabetes/Gastrointestinal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE (page 58)

      Ar Pfalzgraf and Dp Nau

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-29.x

    2. You have free access to this content
      THE INCREMENTAL COST OF DIABETES IN CHRONIC ILLNESS CO-OCCURRENCES (pages 58–59)

      Ri Garis, Kc Farmer and M Arora

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-30.x

  16. Infectious Disease

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT (pages 59–60)

      P Davey, J Wang, K Claxton, E Fenwick, M Sculpher and D Talan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-33.x

  17. Diabetes/Gastrointestinal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN (page 59)

      T Brelje, A Heaton, S Martin, A Bhattacharjya, S Dodd and J Thornhill

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-32.x

    2. You have free access to this content
  18. Infectious Disease

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE CONFUSION BETWEEN SEPTICEMIA AND SEVERE SEPSIS (pages 60–61)

      Wt Linde-Zwirble, De Ball, Lm Cooper, J Lidicker and Dc Angus

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-36.x

    2. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN (page 60)

      B Luce, K Zangwill, C Palmer, P Mendelman, L Yan, M Wolff, I Cho, D Iacuzio and B Belshe

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-35.x

    3. You have free access to this content
      HEALTH VALUES FOR THE LIPODYSTROPHY SYNDROME (page 60)

      La Lenert, M Fedderson, A Sturley and D Lee

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-34.x

  19. Mental Health

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      FUTURE EMPLOYABILITY: A NEW APPROACH TO COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTIC THERAPY (pages 61–62)

      R Ganguly, Ls Miller and Bc Martin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-38.x

    2. You have free access to this content
      THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA (page 61)

      Pm Mulani and J McCombs

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-37.x

    3. You have free access to this content
      CLINICAL ASSESSMENT OF QUALITY OF LIFE AMONG SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME (page 62)

      P Russo and B Kirkpatrick

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-39.x

  20. Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      COST-EFFECTIVENESS OF INTERVENTIONS FOR LATERAL EPICONDYLITIS: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE (pages 62–63)

      Korthals-de Bos Ibc, N Smidt, M Tulder and L Bouter

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-41.x

  21. Mental Health

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      APPLICATION OF THE RASCH MODEL TO THE SF36 MENTAL HEALTH 5 ITEM SCALE (MH5) (page 62)

      Tv Perneger and Pa Bovier

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-40.x

  22. Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      RESPONSIVENESS TO CHANGE OF THE SF-36 IN RAPOLO, A LONGITUDINAL STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT (page 63)

      Dp Lubeck, E Yelin, P Katz, L Roepke, La Wanke and M Buatti

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-42.x

    2. You have free access to this content
      CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT (pages 63–64)

      Ss Kim, Am Drabinski, Gr Williams and Ca Formica

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-43.x

  23. Respiratory Disorders/Diseases

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE (pages 64–65)

      A Szende, A Meszaros, Gy Berta, E Stahl and K Svensson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-46.x

    2. You have free access to this content
      OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA: A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE (page 64)

      Cf Chiou, Mr Weaver and Ma Bell

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-45.x

  24. Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      A SYSTEMATIC REVIEW OF HEALTH STATE VALUES FOR OSTEOPOROSIS RELATED CONDITIONS (page 64)

      Je Brazier, C Green and J Kanis

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-44.x

  25. Respiratory Disorders/Diseases

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA (pages 65–66)

      A Paltiel, A Fuhlbrigge, B Kitch, S Weiss, P Neumann and K Kuntz

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-48.x

    2. You have free access to this content
      PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE: A NEW, PATIENT-BASED MEASURE OF SYMPTOMS IN COMMUNITY ACQUIRED PNEUMONIA (page 65)

      D Lamping, S Schroter, Pp Sagnier and I Duprat-Lomon

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40201-47.x

  26. Arthritis, Osteoporosis & Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
    2. You have free access to this content
      JOINT COUNTS IN PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS: PATIENT VS. PHYSICIAN ASSESSMENT (page 66)

      Ss Kim, Am Drabinski, Gr Williams and Ca Formica

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.004002066.x

    1. You have free access to this content
      Contributed Poster Presentations (pages 66–188)

      Version of Record online: 1 MAY 2002 | DOI: 10.1046/j.1524-4733.2001.00202.x

  27. Arthritis, Osteoporosis & Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE COST OF OSTEOPOROTIC FRACTURES IN THE UNITED KINGDOM (pages 66–67)

      Rt Burge, D Worley, A Johansen and U Bose

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-3.x

    2. You have free access to this content
      INVESTIGATING THE CONSTRUCT VALIDITY OF A DISEASE SPECIFIC AND A GENERAL QUALITY OF LIFE INSTRUMENTS OF PATIENTS WITH RHEUMATOID ARTHRITIS (page 67)

      K Lovas, A Szende, G Bàlint, B Szebenyi and G Héjj

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-5.x

    3. You have free access to this content
      USE OF COX 2 NSAIDS IN SUBJECTS WITHOUT RISK OF GASTROINTESTINAL SIDE EFFECTS (page 67)

      Cr Harley

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-4.x

    4. You have free access to this content
      COST-EFFECTIVENESS OF ROFECOXIB VERSUS NSAIDS IN THE TREATMENT OF OSTEOARTHRITIS (pages 67–68)

      P Sullivan and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-6.x

    5. You have free access to this content
    6. You have free access to this content
      THE CORRELATION BETWEEN ARTHRITIS SPECIFIC MEASURES AND SF-36 SCALES IN RHEUMATOID ARTHRITIS PATIENTS (page 68)

      Dp Lubeck, E Yelin, P Katz, L Roepke, La Wanke and M Buatti

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-7.x

    7. You have free access to this content
    8. You have free access to this content
      APPLYING BACKGROUND RISK DISTRIBUTION TO EVALUATE THE COST-EFFECTIVENESS OF THREE PREVENTIVE DRUG THERAPIES FOR OSTEOPOROTIC FRACTURES (pages 69–70)

      X Gao, S Madhavan, D Nau, A Ambegaonkar, S Islam, S Rosenbluth and M Amonkar

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-11.x

    9. You have free access to this content
      THE IMPACT OF EARLY RHEUMATOID ARTHRITIS ON PRODUCTIVITY (page 69)

      Ss Kim, Am Drabinski, Gr Williams and Ca Formica

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-10.x

    10. You have free access to this content
    11. You have free access to this content
      TREATMENT WITH LEFLUNOMIDE IMPROVES THE UTILITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN APPLICATION OF THE SF-6D (pages 70–71)

      B Crawford, Je Brazier, V Strand and J Doyle

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-14.x

    12. You have free access to this content
      A COST-EFFECTIVENESS MODEL COMPARING CELECOXIB AND ROFECOXIB TO TRADITIONAL NSAIDS FOR OSTEOARTHRITIS TREATMENT (page 70)

      Mg Schaefer, Ap Morreale and Bk Plowman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-13.x

    13. You have free access to this content
      EVALUATING DIRECT AND INDIRECT MEASURES OF UTILITY: STABILITY OF THE SF-6D IN A RHEUMATOID ARTHRITIS POPULATION (page 71)

      B Crawford and Je Brazier

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-15.x

    14. You have free access to this content
      COST IMPACT OF COX-2 INHIBITORS IN A MANAGED CARE PLAN: IMPLICATIONS FOR FORMULARY DECISION-MAKING (pages 71–72)

      De Atherly, Ds Fullerton, Ll Sturm, A Bryant and Sd Sullivan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-16.x

    15. You have free access to this content
      A REVIEW OF FUNCTIONAL STATUS MEASURES FOR WORKERS WITH UPPER EXTREMITY DISORDERS (pages 72–73)

      Df Salerno, C Copley-Merriman, Tn Taylor, J Shinogle and Rm Schulz

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-19.x

    16. You have free access to this content
      PERFORMANCE ASSESSMENT OF TWO FATIGUE INSTRUMENTS IN AN EARLY RHEUMATOID ARTHRITIS COHORT (page 72)

      A Drabinski, Ss Kim, G Williams and C Formica

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-18.x

    17. You have free access to this content
      IMPORTANT ISSUES IN NUMBER NEEDED TO TREAT ANALYSIS IN OSTEOPOROSIS TREATMENT (page 72)

      Je Kemner

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-17.x

    18. You have free access to this content
      MANUAL THERAPY IS MORE COST-EFFECTIVE THAN PHYSICAL THERAPY AND GP CARE FOR PATIENTS WITH NECK PAIN (page 73)

      Korthals-de Bos Ibc, J Hoving, M Tulder and L Bouter

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-21.x

    19. You have free access to this content
      COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50% FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY (page 73)

      Hem Van Dieten, Rsg Perez, Mw Tulder, M Boers, Wwa Zuurmond, Jj De Lange, H Vondeling and M Boers

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-20.x

    20. You have free access to this content
      STUDYING PREDICTORS OF FRACTURES AMONG OMNICARE NURSING HOME RESIDENTS (pages 73–74)

      Gm Oderda, D Gause, B Stuart and G Erwin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-22.x

  28. Asthma & Respiratory Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK (pages 74–75)

      E Prosekova, B Geltzer, V Dercach and P Bogdanovskiy

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-24.x

  29. Arthritis, Osteoporosis & Musculoskeletal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      VERTEBRAL FRACTURES AMONG GLUCOCORTICOID PATIENTS SIGNIFICANTLY INCREASE MEDICAL CARE COSTS (page 74)

      Jw Meyer, Rt Burge and M Steinbuch

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-23.x

  30. Asthma & Respiratory Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S): DOES SOCIOECONOMIC STATUS EFFECT MEASUREMENTS? (pages 75–76)

      Ld Lynd, D Guh, P Pare and A Anis

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-26.x

    2. You have free access to this content
      USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES (page 75)

      Bg Silverman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-25.x

    3. You have free access to this content
      DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS (page 76)

      Hg Birnbaum, Ma Morley, Pe Greenberg, M Cifaldi and Gl Colice

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-28.x

    4. You have free access to this content
      COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (page 76)

      Re Aubert, B Alemayehu and R Feifer

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-27.x

    5. You have free access to this content
      PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS (pages 76–77)

      R Balkrishnan, D Christensen and D Bowton

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-29.x

    6. You have free access to this content
      VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE (page 77)

      P Sullivan and M Nichol

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-30.x

    7. You have free access to this content
      VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA (pages 77–78)

      Fg Pradel, S Weiss, M Tsoukleris, Mb Bollinger and C Fahlman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-32.x

    8. You have free access to this content
    9. You have free access to this content
    10. You have free access to this content
      IMPLEMENTING RASCH ANALYSIS IN PSYCHOMETRIC EVALUATION OF PATIENT-PHYSICIAN INTERACTION SCALE (page 78)

      M Dalal, E Smith, B Lambert, C Olopade and S Crawford

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-33.x

    11. You have free access to this content
      ASSESSMENT OF THE RELATIONSHIP BETWEEN DISEASE SEVERITY, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA (pages 79–80)

      A Zillich, K Blumenschein, M Johannesson and P Freeman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-37.x

    12. You have free access to this content
      HYPOTHETICAL VERSUS REAL WILLINGNESS TO PAY IN THE HEALTH CARE SECTOR: RESULTS FROM A FIELD EXPERIMENT (page 79)

      K Blumenschein, M Johannesson, K Yokoyama and P Freeman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-36.x

    13. You have free access to this content
      PROSPECTIVE USE OF WEB BASED TECHNOLOGY TO EVALUATE HEALTH OUTCOMES IN A LARGE COHORT OF SEVERE OR DIFFICULT TO TREAT ASTHMATICS (page 79)

      Cm Dolan, Ka Fisher, C Johnson, Ke Fraher, Ea Rothermich, Jt Fine, St Weiss and S Wenzel

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-35.x

    14. You have free access to this content
      COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION (page 80)

      Ep Armstrong, Dc Malone and Ra Rehfeld

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-39.x

    15. You have free access to this content
      COMPARISON OF HEALTH CARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO (page 80)

      I Bagchi, A Bakst, J Edelson and O Amit

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-38.x

    16. You have free access to this content
      PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES (pages 80–81)

      S Sahu and R Millard

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-40.x

    17. You have free access to this content
    18. You have free access to this content
      IMPACT OF THE ADDITION OF SALMETEROL TO THE TREATMENT OF ASTHMA PATIENTS IN A MEDICAID FEE-FOR-SERVICE POPULATION (page 81)

      Lm Klaurens, Ma Dodd, Gv Gupchup, Hw Kelly and J Hollarbush

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-42.x

    19. You have free access to this content
      COSTS OF TREATING COPD IN ITALY: A BURDEN OF ILLNESS STUDY (page 81)

      A Bonzanini, R Avossa, E Scipioni and F Gianfrate

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-41.x

    20. You have free access to this content
      IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES (pages 82–83)

      D Huse, A McLoney, B Yeager and F Cerasoli

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-45.x

    21. You have free access to this content
      LEVALBUTEROL USE IS ASSOCIATED WITH DECREASED HEALTH CARE COSTS IN PATIENTS WITH MORE SEVERE ASTHMA (page 82)

      D Huse, A McLoney, B Yeager and F Cerasoli

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-44.x

    22. You have free access to this content
      DETERMINANTS OF INAPPROPRIATE ANTIBIOTIC PRESCRIBING (page 83)

      Mk Willis

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-46.x

  31. Cancer

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
    2. You have free access to this content
      CATEGORIZATION OF RISK OF PROSTATE CANCER: PILOT TEST OF CLINICAL OUTCOMES AND RISK PERCEPTIONS (page 83)

      Dw Bruner, Aa Parlanti, E Ross, S Raysor, Se Mazzoni and Ge Hanks

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-47.x

    3. You have free access to this content
      PREDICTORS OF CHEMOTHERAPY-RELATED NEUTROPENIA: A REVIEW OF THE CLINICAL LITERATURE (page 84)

      C Palmer, R Brown, M Wilson-Royalty and G Lawless

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-49.x

    4. You have free access to this content
      COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES (pages 84–85)

      Dd Gagnon, Sc Martin and B Van Hout

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-50.x

    5. You have free access to this content
      CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS? (pages 85–86)

      Sk Thomas, Se Brooks and Cd Mullins

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-52.x

    6. You have free access to this content
    7. You have free access to this content
      ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK (pages 86–87)

      M Lees, M Aristides, N Botwood, J McKendrick, N Maniadakis, W Wein and D Stephenson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-55.x

    8. You have free access to this content
      ECONOMIC EVALUATION OF GEMZAR IN THE TREATMENT OF PANCREATIC CANCER IN THE UK (page 86)

      D Stephenson, N Botwood, J McKendrick, M Aristides, M Lees, N Maniadakis and W Wein

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-54.x

    9. You have free access to this content
      ECONOMIC EVALUATION OF GEMZAR AND BEST SUPPORTIVE CARE (BSC) RELATIVE TO BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK (page 86)

      J McKendrick, N Botwood, M Aristides, M Lees, N Maniadakis, W Wein and D Stephenson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-53.x

    10. You have free access to this content
      COST-EFFECTIVENESS MODEL OF PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR PROSTATE CANCER (page 87)

      L Sokolskiy and Jw Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-56.x

    11. You have free access to this content
      ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK (pages 87–88)

      Dh Smith, Mf Drummond, S Johnston and A Gordon

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-57.x

    12. You have free access to this content
      COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER (page 88)

      Ls Elting, Cg Martin, L Hamblin and Q Chau

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-59.x

    13. You have free access to this content
      COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER (page 88)

      R Hauser, R Theriault, M Shepherd, K Lawson, J Wilson and J Koeller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-58.x

    14. You have free access to this content
      CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION: A COMPARISON OF OUTCOMES AND COSTS (pages 88–89)

      D Polsky, L Venditti, Js Mandelblatt, Jc Weeks, J Hadley, Yt Hwang and K Schulman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-60.x

    15. You have free access to this content
      DIFFERENCES BETWEEN PREFERENCES FOR HEALTH STATES: THE CHEMOTHERAPY ADVERSE EVENT SELF-ASSESSED RESPONSE (CAESAR) QUESTIONNAIRE (page 89)

      Ag Purdum, D Globe, A Mathes and Mb Nichol

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-61.x

    16. You have free access to this content
      CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION (pages 89–90)

      C Yazdani, T McLaughlin, F Koos and J Hansen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-62.x

    17. You have free access to this content
      COLORECTAL CANCER SCREENING TESTS: VARIATION IN PREFERENCES BASED ON GENDER AND RACE (pages 90–91)

      W Straus, P Schaffner, K Gold, C Pashos and E Mansley

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-65.x

    18. You have free access to this content
      COLORECTAL CANCER SCREENING: AWARENESS, UTILIZATION, AND BARRIERS (page 90)

      W Straus, P Schaffner, K Gold, C Pashos and E Mansley

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-64.x

    19. You have free access to this content
      AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK (page 90)

      S Sorensen, R Brown, E De Cock and A Bearne

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-63.x

    20. You have free access to this content
      HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER (pages 91–92)

      Dp Lubeck, Gd Grossfeld and Pr Carroll

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-67.x

    21. You have free access to this content
      COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA (page 91)

      P Vorobjov, V Fisenko, V Gerasimov, M Avxentieva, Moscow Medical Academy, Moscow and Russia

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-66.x

    22. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER (page 92)

      R Hauser and J Koeller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-68.x

    23. You have free access to this content
      INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER (pages 92–93)

      Te Delea, M Vera-Llonch, Js Edelsberg, L McGarry, S Anton, M Ulcickas-Yood and G Oster

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-70.x

    24. You have free access to this content
      DISEASE MODELING: DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL (page 92)

      Rv Becker, L Noe, M Gore, S Martino, W Eiermann, M Namer, A Howell, A Bianco and T Watanabe

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-69.x

    25. You have free access to this content
      A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION (page 93)

      Kr Musgrave, D Wyld and R Abraham

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-71.x

    26. You have free access to this content
    27. You have free access to this content
      DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICALPRACTICE: NEED FOR A CHANGE? (page 94)

      L Hooft and Os Hoekstra

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-74.x

    28. You have free access to this content
      COST OF TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN THE UNITED STATES (page 94)

      K Cronin, B Lee and D Wang

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-73.x

  32. Cardiovascular Disease

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE (pages 94–95)

      Mc Decerbo, Sa Baroletti, S Isopo, M Silva and Dk Talati

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-75.x

    2. You have free access to this content
      ASSESSING QUALITY OF LIFE IN PATIENTS SIX MONTHS AFTER A MYOCARDIAL INFARCTION USING THE SF-12 (pages 95–96)

      Cr McBurney, Sr Erickson, Em Kline-Rogers, Jv Cooper, Ocm Mani and Ka Eagle

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-78.x

    3. You have free access to this content
      AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS (page 95)

      Cr McBurney and D Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-77.x

    4. You have free access to this content
      VENOUS THROMBOEMBOLIC (VTE) COMPLICATIONS FOLLOWING MAJOR ORTHOPEDIC SURGERY: FREQUENCY AND ECONOMIC CONSEQUENCES IN HOSPITAL (page 95)

      S Gabriel, J Dinet, T Dispot and C Radal

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-76.x

    5. You have free access to this content
      ESTIMATING INCREMENTAL COSTS FOR ADDITIONAL HOSPITAL DAYS (pages 96–97)

      Jy Friedman, Sd Reed, A Gnanasakthy and Ka Schulman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-80.x

    6. You have free access to this content
      COST OF TREATMENT AND PREVALENCE OF CARDIOVASCULAR DISEASE COMORBIDITIES AND RISK FACTORS IN THE SEVERE AND PERSISTENTLY MENTALLY ILL (page 96)

      Tj Bellnier, A Labrum, Sd Karki and J Sundberg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-79.x

    7. You have free access to this content
      AN ECONOMIC ANALYSIS OF CONGESTIVE HEART FAILURE (CHF) IN THE LOUISIANA MEDICAID PROGRAM (pages 97–98)

      Ss Ogale, Sg Blake, Gc Biglane and Pj Medon

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-83.x

    8. You have free access to this content
      PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS: DATABASE ANALYSIS IN FRANCE (page 97)

      C Baptiste and C Guilhaume

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-82.x

    9. You have free access to this content
      COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION (page 97)

      Wf McGhan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-81.x

    10. You have free access to this content
      COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE (pages 98–99)

      Ah Abdelhafiz and N Wheeldon

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-85.x

    11. You have free access to this content
    12. You have free access to this content
      IMPACT ON QUALITY ADJUSTED LIFE YEARS OF ENOXAPARIN FOR PREVENTING THROMBOSIS AMONG HOSPITALIZED MEDICAL PATIENTS (page 99)

      Dw Raisch, Cl Fye, Mr Sather, Wg Henderson, Dj Reda, Jm Sacks and Fl Lederle

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-87.x

    13. You have free access to this content
      QUALITY OF CARE IN OLDER PATIENTS ADMITTED TO HOSPITAL WITH HEART FAILURE (page 99)

      Ah Abdelhafiz and N Wheeldon

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-86.x

    14. You have free access to this content
      IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): AN ANALYSIS OF BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA (pages 99–100)

      M Hassan, Av Joshi, S Madhavan and M Amonkar

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-88.x

    15. You have free access to this content
      ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION (page 100)

      E Liao, M Fronk, J Newell and D Huse

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-89.x

    16. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND (pages 100–101)

      E Orlewska, A Budaj and D Tereszkowski-Kaminski

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-90.x

    17. You have free access to this content
      DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS (pages 101–102)

      Rj Milne, Gd Gamble, G Whitlock, Rj Irwin and Rt Jackson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-93.x

    18. You have free access to this content
      FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY (page 101)

      Rj Milne, Gd Gamble, G Whitlock and Rt Jackson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-92.x

    19. You have free access to this content
      QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS (page 101)

      Gp Shin, Jf Tooley, Mr Southworth, S Dunlap, Jg Boyer and Ne Johnson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-91.x

    20. You have free access to this content
      IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE—THE VA EXPERIENCE (pages 102–103)

      Gj L'Italien, Ls Williams and M Weinberger

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-96.x

    21. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES (page 102)

      J Shahriar, Jw Shaw and D Malone

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-95.x

    22. You have free access to this content
      ASSESSING THE TOTAL COST OF MANAGEMENT OF A PATIENT WITH DEEP VEIN THROMBOSIS (DVT) IN FRANCE AND IN ITALY (page 102)

      E Levy, S Gabriel, J Dinet and G Rudelli

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-94.x

    23. You have free access to this content
      BEYOND THE FIRST YEAR: PATTERNS AND PREDICTORS OF LONG-TERM STATIN UTILIZATION (pages 103–104)

      Js Benner, Ad Federman, Al Smitten, S Duty, Rj Glynn and J Avorn

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-98.x

    24. You have free access to this content
    25. You have free access to this content
      CARING FOR HYPERTENSION ON INITIATION: COSTS AND EFFECTIVENESS (CHOICE). DESIGN AND RATIONALE OF A NATURALISTIC STUDY (page 104)

      K Payne, J Caro, N Hollenberg, J Jackson, G L'Italien and For The Choice Study Group

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-100.x

    26. You have free access to this content
      CHD RISK FACTORS AND THERAPY DURATION OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN A MEDICAID POPULATION (page 104)

      Mb Nichol, Ms Bron and W Yu

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-99.x

    27. You have free access to this content
      A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS (pages 104–105)

      Wj Spruill, We Wade and Rb Leslie

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-101.x

    28. You have free access to this content
      COST-EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION (pages 105–106)

      P Mulani and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-104.x

    29. You have free access to this content
    30. You have free access to this content
      CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER (page 105)

      Js Graff, M Plante and D Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-102.x

    31. You have free access to this content
      STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS (pages 106–107)

      Jh Coombs, L Cornish, P Hiller and Dg Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-106.x

    32. You have free access to this content
    33. You have free access to this content
      COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY (page 107)

      A Spannheimer, O Mast, T Schlereth, Im Thate-Waschke and W Dietrich

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-107.x

    34. You have free access to this content
    35. You have free access to this content
      DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT: A CANADIAN PERSPECTIVE (page 107)

      K Sridhar, F Gwadry, B Kidwai, D Almond and P Teefy

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-108.x

    36. You have free access to this content
      THE COST-EFFECTIVENESS OF STATINS: EVIDENCE FROM THE ACCESS TRIAL (pages 108–109)

      Dg Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-111.x

    37. You have free access to this content
      EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA (page 108)

      Jh Coombs, L Cornish, P Hiller and Dg Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-110.x

    38. You have free access to this content
      COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA (page 109)

      J Wlodarczyk, Pj Barter, R O'Brien, D Talmont and M Ortiz

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-113.x

    39. You have free access to this content
      WITHDRAWN (page 109)

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-112.x

    40. You have free access to this content
    41. You have free access to this content
      COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM (page 109)

      Rn Kumar, Me Borrego, Gv Gupchup, Jr Anderson, Rw Burden and Dl Phillips

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-114.x

    42. You have free access to this content
      PATIENTS' WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES (page 110)

      Pk Wong and R Jang

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-116.x

  33. Diabetes

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DIABETIC MANAGEMENT THROUGH ORAL GLUCOSE LOWERING AGENTS: TREATMENT PATTERN, COST AND UTILIZATION ANALYSIS (pages 110–111)

      Fd Thompson, Ms Rosenblum, Jm O'Neill, D Celebi and E Olmsted

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-118.x

  34. Cardiovascular Disease

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      SEE PCV8 (page 110)

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-117.x

  35. Diabetes

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS (page 111)

      C Henriques, D Schultz, T Milanette, K Todoroff and M Kim

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-119.x

    2. You have free access to this content
    3. You have free access to this content
      THE BURDEN OF ILLNESS OF DIABETES MELLITUS TYPE 2 IN GERMANY— A PILOT STUDY (page 111)

      M Tepe, A Kilburg, D Daniel, D Kirchhoff and R Rychlik

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-120.x

    4. You have free access to this content
      A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY (page 112)

      Ls Lal and Ki Ogbonnaya

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-122.x

    5. You have free access to this content
      AN EARLY LOOK AT TZD USE AMONG TYPE 2 DIABETES PATIENTS (pages 112–113)

      Vf Schabert, M Guo, Je Conklin and Ca Neslusan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-123.x

    6. You have free access to this content
      COST-EFFECTIVENESS ANALYSIS OF A MULTIDISCIPLINARY DIABETES CARE CLINIC (pages 113–114)

      Kk Yokoyama, Kc Griffin, Pj Godley, Ak Cryar and Bw Woodward

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-126.x

    7. You have free access to this content
      FACTORS ASSOCIATED WITH PRESCRIPTION CLAIMS FOR BLOOD GLUCOSE TEST STRIPS AMONG FEE-FOR-SERVICE NEW MEXICO MEDICAID PATIENTS (page 113)

      Cj Cordova, Bm Shah, Ma Dodd and Gv Gupchup

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-125.x

    8. You have free access to this content
      COSTS AND EFFECTIVENESS OF INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES (page 113)

      A Hisashige, T Katayama and H Mikasa

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-124.x

    9. You have free access to this content
      A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE (pages 114–115)

      Kk Lee, Jh You, Ss Ho, Wy Leung, G Thomas, Ty Chan and J Critchley

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-129.x

    10. You have free access to this content
      ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION (page 114)

      Sa Leong, Kh Summers, Hg Birnbaum, Je Kemner, Ec Lentz and Pe Greenberg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-128.x

    11. You have free access to this content
      THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS (page 114)

      Rs Woodward, Ma Schnitzler, Ja Lowell, S Haider and Dc Brennan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-127.x

    12. You have free access to this content
      IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM: A RETROSPECTIVE CLAIMS-BASED EVALUATION (page 115)

      J Berger, J Slezak, W O'Leary, P McStay, K Johnson and J Addiego

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-131.x

    13. You have free access to this content
      OPTIMIZATION OF DIABETES MANAGEMENT IN GERMANY USING A COMPUTER BASED OUTCOME PROGNOSES MODEL (page 115)

      A Brandt, V Gozzoli, A Palmer, C Weiss, K Neeser and W Schramm

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-130.x

    14. You have free access to this content
      DOES PATIENT EXPERIENCE MATTER? TYPE II DIABETES PATIENTS' STATED PREFERENCES FOR INSULIN THERAPIES (pages 115–116)

      G Smith, M Bingham, Fr Johnson and B Bolinder

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-132.x

  36. Eye/Ear/Skin/Dental

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
  37. Diabetes

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      AN OVERVIEW OF PHARMACOECONOMICS IN TURKEY: COST ANALYSIS AND REIMBURSEMENT OF ANTIDIABETIC DRUGS (page 116)

      Ah Sapci, Ha Sapci and R Demirdamar

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-133.x

  38. Eye/Ear/Skin/Dental

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYER'S PERSPECTIVE (page 117)

      Mk Higashi, D Veenstra, M Del Aguila and P Hujoel

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-135.x

    2. You have free access to this content
      THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX (pages 117–118)

      A Finlay, M Corvest, P Lefrançois and C Taieb

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-137.x

    3. You have free access to this content
      DRY-EYE RELATED INCREASES IN HEALTH CARE UTILIZATION AND EXPENDITURES (page 117)

      Je Smeeding, T McLaughlin, C Yazdani and Jg Walt

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-136.x

    4. You have free access to this content
      COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS (page 118)

      Ms Bron and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-139.x

    5. You have free access to this content
      INAPPROPRIATE ANTIBIOTIC PRESCRIBING AND ECONOMIC OUTCOMES FOR PEDIATRIC OTITIS MEDIA (page 118)

      Am Rahman, J Feldhaus, L Lawrence, H Rappaport and E Moser

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-138.x

    6. You have free access to this content
      A COST COMPARISON STUDY OF COMMON PRACTICE AND BEST PRACTICE TREATMENT FOR PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES (pages 118–119)

      Sj Evans, J Casciano, Jj Doyle and Jg Walt

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-140.x

    7. You have free access to this content
      FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG) (page 119)

      E Yu, J Hay, R Varma and D Globe

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-141.x

  39. Gastrointestinal Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
    2. You have free access to this content
      A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES (page 120)

      Km Shermock, Jj Vargo, G Zuccaro and Wg Maurer

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-144.x

    3. You have free access to this content
      ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA (page 120)

      Eq Wu and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-143.x

    4. You have free access to this content
      HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA REVEAL DIFFERENCES AMONG CLINICAL “RESPONDERS” (pages 120–121)

      Me Watson, At Heath and Ar Northcutt

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-145.x

    5. You have free access to this content
      BUDESONIDE CIR IS COST-EFFECTIVE IN MAINTENANCE THERAPY OF CROHN'S DISEASE IN FINLAND (pages 121–122)

      K Ericsson, Al Karvonen, H Sintonen and S Borg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-148.x

    6. You have free access to this content
    7. You have free access to this content
      HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE (page 121)

      K Ericsson, R Löfberg, Å Danielsson, Ch Floren and S Borg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-146.x

    8. You have free access to this content
    9. You have free access to this content
      RAPID IMPACT OF RABEPRAZOLE ON SYMPTOM DISTRESS AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (page 122)

      A Damiano, E Adler, R Siddique, S Sloan and A Bhattacharjya

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-149.x

    10. You have free access to this content
      ESTIMATING POTENTIAL UTILIZATION OF ESOMEPRAZOLE BY ASSESSING GERD SYMPTOM CONTROL ON TRADITIONAL PPI'S (pages 123–124)

      Ml DeLattre, M Schaefer, Ap Morreale and Bk Plowman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-153.x

    11. You have free access to this content
      CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTH CARE PLAN (page 123)

      T Brelje, A Heaton, S Martin, A Bhattacharjya, S Dodd and J Thornhill

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-152.x

    12. You have free access to this content
      IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR (page 123)

      Hj Schultes, W Guminski, U Rosche, B Ries and O Pirk

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-151.x

    13. You have free access to this content
      HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS? (pages 124–125)

      P Davey, G Libby, K Hunter, J Broomhall, D Kofteridis, D Steinke, E Taylor and D Yin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-155.x

    14. You have free access to this content
      FACTORS ASSOCIATED WITH PHYSICIAN KNOWLEDGE OF WHETHER PRESCRIPTION DRUGS ARE ON FORMULARY (page 124)

      Yct Shih and B Sleath

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-154.x

    15. You have free access to this content
      ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE (page 125)

      L Annemans, K Moeremans, P Rutgeerts and L Lemmens

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-157.x

    16. You have free access to this content
      COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY (page 125)

      E Kroch, K Azimuddin, L Rosen and Jf Reed

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-156.x

    17. You have free access to this content
      COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHN'S DISEASE (pages 125–126)

      Jd Wurtzbacher, Gk Gourley, Pj Reed, Dr Gourley, Dk Solomon and Jw Haas

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-158.x

  40. Infectious Diseases

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS: A META-ANALYSIS REVISITED (page 126)

      N Chaiyakunapruk, Dl Veenstra, Sd Sullivan, S Saint and S Bent

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-159.x

    2. You have free access to this content
      IMPACT OF CYTOMEGALOVIRUS (CMV)-RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE (pages 126–127)

      S Leader, R Henderson and D Carlin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-160.x

    3. You have free access to this content
    4. You have free access to this content
      ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS: AN EMPLOYER'S PERSPECTIVE (page 127)

      U Chaikledkaew, Gg Liu, R Lyu and S Louie

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-162.x

    5. You have free access to this content
      TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES (page 127)

      Cf Bell, Jm Stephens, Mf Botteman, Cl Pashos and M Ewing

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-161.x

    6. You have free access to this content
      OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS (pages 128–129)

      A Drabinski, G Williams and C Formica

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-165.x

    7. You have free access to this content
      HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? (page 128)

      Br Schackman, Sj Goldie, Ka Freedberg, E Losina, J Brazier and Mc Weinstein

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-164.x

    8. You have free access to this content
      COSTS OF HEALTH CARE FOR HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO) (page 129)

      M Schaffer, Al Phillips and S Mansukani

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-166.x

    9. You have free access to this content
      EFFECTS OF LINEZOLID ON HOSPITAL LENGTH OF STAY IN METHICILLIN-RESISTANT STAPHYLOCOCCUS INFECTIONS ESTIMATED FROM MULTIVARIATE SURVIVAL ANALYSIS (pages 129–130)

      Rj Willke, Zj Li, H Glick, Be Rittenhouse and B Hafkin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-168.x

    10. You have free access to this content
      COST-EFFECTIVENESS OF INTERFERON ALFA THERAPY FOR CHRONIC HEPATITIS C WITH CIRRHOSIS (page 129)

      A Hisashige, T Katayama and H Mikasa

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-167.x

    11. You have free access to this content
      PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS®) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C (page 130)

      J Imperial, P Thuluvath, Rp Perrillo, Kd Rothstein, Ns Poulios, Sc Pappas, Sp Ackermann and Bs Doerschuk

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-169.x

    12. You have free access to this content
      AVERTING FUTURE AIDS CASES: MODELING COSTS OF INTERVENTIONS WITH OUT-OF-TREATMENT SUBSTANCE ABUSERS (pages 130–131)

      A Richter, Br Loomis and Wm Wechsberg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-170.x

    13. You have free access to this content
      PREDICTORS OF THE MENTAL (MHS) AND PHYSICAL HEALTH SUMMARY (PHS) SCORES OF THE MOS-HIV IN A SAMPLE OF HIV-INFECTED PATIENTS (page 131)

      Dl Griffis, T Delate and Sj Coons

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-172.x

    14. You have free access to this content
      ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION FOR THE NETHERLANDS (page 131)

      R Welte, J Jager, Y Van Duynhoven and M De Wit

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-171.x

    15. You have free access to this content
      MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY: CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS (pages 131–132)

      Ja O'Brien, D Pierce, Ar Patrick and Jj Caro

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-173.x

    16. You have free access to this content
      ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN (page 132)

      M Kobayashi

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-175.x

    17. You have free access to this content
      COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING (page 132)

      M Schaffer, M Liu, W Scott and S Mansukani

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-174.x

    18. You have free access to this content
      METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA (pages 132–133)

      D Becker and Aj Rosner

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-176.x

    19. You have free access to this content
      TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION (pages 133–134)

      B Doyle and G Hess

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-178.x

    20. You have free access to this content
      AN ECONOMIC ANALYSIS OF CEFDINIR VERSUS LORACARBEF FOR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (page 133)

      Sn Shah, D Smith and C Copley-Merriman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-177.x

    21. You have free access to this content
    22. You have free access to this content
      PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS: AN ANALYSIS OF MANAGED-CARE DATA (pages 134–135)

      B Edelman-Lewis, J Menzin, L Boulanger, M Leung, M Friedman, Js Hurley, J Harnett and J Wilson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-181.x

    23. You have free access to this content
    24. You have free access to this content
      ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS (pages 135–136)

      J Lachaine, C Laurier and P Manzi

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-183.x

    25. You have free access to this content
      COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION (page 135)

      Tj Bell, Br Loomis, Ja Mauskopf, Gj L'Italien and Km Gallagher

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-182.x

    26. You have free access to this content
      DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS (page 136)

      Md Rousculp

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-185.x

    27. You have free access to this content
      PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY (page 136)

      O Karpov and A Zaytsev

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-184.x

    28. You have free access to this content
      COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS (pages 136–137)

      R Reynolds, G Gupchup, M Borrego, D Raisch and S Netravali

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-186.x

  41. Mental Health

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
    2. You have free access to this content
      SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED? (page 137)

      J Barr, G Schumacher, E Mason, S Ohman, J Goren and A Hanson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-187.x

    3. You have free access to this content
      ASSESSMENT OF PATIENTS' ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL (page 138)

      A Dugar, Je Stuelpner, Ja Mackell and Rj Miceli

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-190.x

    4. You have free access to this content
      IS DEPRESSION THE MAJOR CAUSE OF IMPAIRED QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS? (page 138)

      M Toumi, Å Pettersson, Pm Llorca, C Lançon and S Aballéa

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-189.x

    5. You have free access to this content
    6. You have free access to this content
      CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS (pages 139–140)

      Se Jensik, Kw Mayo, Kl Bailey, Ri Sandoval, Ws Edell and Be Adams

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-193.x

    7. You have free access to this content
      CHANGE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS (page 139)

      Ws Edell, Kw Mayo, Kl Bailey, Ri Sandoval, Be Adams and Se Jensik

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-192.x

    8. You have free access to this content
      IMPACT OF CURRENT ANTIDEPRESSANTS ON COGNITION IN OLDER PATIENTS WITH DEPRESSION (page 140)

      Be Adams, Kw Mayo, Ri Sandoval, Kl Bailey, Se Jensik and Ws Edell

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-194.x

    9. You have free access to this content
    10. You have free access to this content
      HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION (page 140)

      Km Shermock, Ma Fuller, M Secic, Js Laich and Mb Durkin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-195.x

    11. You have free access to this content
      PREVALENCE OF COMORBID ANXIETY AND DEPRESSION AMONG PATIENTS PRESCRIBED SSRI MONOTHERAPY (pages 141–142)

      Km Grotzinger and Ll Chang

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-198.x

    12. You have free access to this content
    13. You have free access to this content
    14. You have free access to this content
      PRE-TREATMENT PATIENT DIFFERENCES: CHOICE OF DRUG THERAPY WITHIN SCHIZOPHRENIA (page 142)

      Pj Gibson and Dl Loosbrock

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-199.x

    15. You have free access to this content
      DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE (page 142)

      P Russo and B Kirkpatrick

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-200.x

    16. You have free access to this content
      TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES USING A MARKOV MODEL (page 143)

      K Neeser, W Schramm, A Brandt, J Höffler, T Jürgens and O Mast

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-203.x

    17. You have free access to this content
      USE OF RASCH MODELS FOR VALIDATION OF INSTRUMENTS USED IN MENTAL HEALTH EVALUATION (page 143)

      C Lançon, M Toumi, Å Pettersson, S Aballéa and A Fournier

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-202.x

    18. You have free access to this content
      HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION (pages 143–144)

      Wh Crown, Dcy Ling, Sn Finkelstein, Er Berndt and As White

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-204.x

    19. You have free access to this content
      DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS (pages 144–145)

      Jk Young, D Schultz, D Foster and S Heller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-206.x

    20. You have free access to this content
      RISK OF HOSPITALIZATION FOR PATIENTS WITH BIPOLAR DISORDER (page 144)

      Dcy Ling, Bw Bresnahan, As White, Ca Neslusan and Wh Crown

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-205.x

    21. You have free access to this content
    22. You have free access to this content
      PATTERNS OF ANTIDEPRESSANT USE AND HEALTH CARE COSTS IN DEPRESSED PATIENTS WHO RECEIVED SSRI THERAPY (page 145)

      Sw Wade, R Berzon, Mp Patton, P Koch and D Batra

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-208.x

    23. You have free access to this content
      QUALITY OF LIFE OF NON-INSTITUTIONAL CAREGIVERS OF SCHIZOPHRENIC PATIENTS: CONTRIBUTION OF QUALITATIVE INTERVIEWS TO QUESTIONNAIRE GENERATION (page 145)

      P Auquier, Mc Simeoni, Jm Azorin, C Lançon and M Toumi

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-207.x

    24. You have free access to this content
      A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA (pages 146–147)

      I Alexeyeva, J Mauskopf, S Earnshaw, Pj Gibson, H Ascher-Svanum and Jl Ramsey

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-211.x

    25. You have free access to this content
      THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA (page 146)

      Ja O'Brien and Ar Patrick

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-210.x

    26. You have free access to this content
    27. You have free access to this content
      DEPRESSION AND HOMELESSNESS, A FRENCH INITIATIVE (pages 147–148)

      X Emmanuelli, J Hassin, C Smadja and C Taieb

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-214.x

    28. You have free access to this content
    29. You have free access to this content
    30. You have free access to this content
      PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN “REVOLVING DOOR” SCHIZOPHRENIC PATIENTS (pages 148–149)

      I Gurovich, E Lyubov and A Shmukler

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-217.x

    31. You have free access to this content
      DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY (page 148)

      W Crown, Gj Wan, Er Berndt, Sn Finkelstein and D Ling

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-216.x

    32. You have free access to this content
      OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA: A COMPARISON OF COSTS AMONG TEXAS MEDICAID PATIENTS (pages 149–150)

      Kl Rascati, M Johnsrud, Ml Crismon, Bl Barber and Mj Lage

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-219.x

    33. You have free access to this content
      BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM (page 149)

      Tl Mark, Hr Kranzler, Vh Poole, Ca Hagen, C McLeod and Se Crosse

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-218.x

    34. You have free access to this content
      PATTERNS OF ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATION USE IN MEDICAID, 1995–1999 (page 150)

      R Gregorian and E Gemmen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-221.x

    35. You have free access to this content
      SWITCHING AND AUGMENTATION OF ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS (page 150)

      Be Adams, Se Jensik, Kw Mayo, Kl Bailey, Ri Sandoval and Ws Edell

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-220.x

    36. You have free access to this content
      DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS (pages 150–151)

      Jk Young, D Schultz, D Foster and S Heller

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-222.x

  42. Pain & Neurologic Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      USE OF GALANTAMINE IN THE NETHERLANDS FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE (pages 151–152)

      J Caro, M Salas, D Getsios, A Mehnert and For The Ahead Study Group

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-224.x

    2. You have free access to this content
      AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES (page 151)

      La Lenert, C Minh and C Jackson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-223.x

    3. You have free access to this content
      THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE (page 152)

      Kf Gold, Mf Botteman, R Kemp, B Kittner and Cl Pashos

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-225.x

    4. You have free access to this content
      COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES (pages 152–153)

      G Bazalo, R Sachdeo, S Graham, S Chang and A Cohen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-227.x

    5. You have free access to this content
      UTILITY ASSESSMENTS OF OPIOID TREATMENT IN THE US, CANADA AND AUSTRALIA FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN (page 152)

      J Schmier, C Palmer, M Ingham, S Mathur, S Dodd and G Gourlay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-226.x

    6. You have free access to this content
      VALIDATION OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) IN A SAMPLE OF HEADACHE SUFFERERS (page 153)

      Mc Runken, W Kwong, K Davis and A Batenhorst

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-228.x

    7. You have free access to this content
      A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION (pages 153–154)

      J Shaw, V Joish and Ps Cady

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-229.x

    8. You have free access to this content
      PSYCHOMETRIC EVALUATION OF WIDELY USED PAIN MEASURES FOR PURPOSE OF COMPUTERIZED DYNAMIC PAIN ASSESSMENT (page 154)

      Jh Zhao, Je Ware, M Kosinski, Jb Bjorner and D Turner-Bowker

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-230.x

    9. You have free access to this content
      SURVIVAL AND NURSING HOME FREE SURVIVAL (NHFS) OF AD PATIENTS (pages 154–155)

      Eq Wu and J Hay

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-232.x

    10. You have free access to this content
      HOW IS PAIN FELT ACROSS COUNTRIES? THE SHORT-FORM MCGILL PAIN QUESTIONNAIRE (SF-MPQ) IN 10 LANGUAGES (page 154)

      K Conway, V Uzun, J Alacoque, L Abetz, R Melzack and M Plante

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-231.x

    11. You have free access to this content
      DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE (page 155)

      Tk Girts, Jh Lofland and Jp O'Connor

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-234.x

    12. You have free access to this content
      THE MIGRAINE IN FRANCE IN 2000: EPIDEMIOLOGICAL DATA (page 155)

      P Henry, Jp Auray, G Duru, G Chazot, Jf Dartigues, M Lanteri-Minet, C Lucas, A Pradalier, A El Hasnaoui and Af Gaudin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-233.x

    13. You have free access to this content
      DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMER'S DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTH CARE COST-SAVING IMPLICATIONS (pages 155–156)

      G Provenzano, S Duttagupta, T McRae, V Mastey, B Ellis and J Ieni

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-235.x

    14. You have free access to this content
      MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN (pages 156–157)

      A Szende, Zs Kincses, M Zimanyi, Z Kadar and G Zorenyi

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-237.x

    15. You have free access to this content
      A PROGNOSTIC MODEL TO PREDICT QUALITY OF LIFE CHANCES AFTER SUBARACHNOID HEMORRHAGE (page 156)

      K Toth, A Szende, M Contreraz, A Machovich, J Futo and I Nyari

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-236.x

    16. You have free access to this content
      ADDRESSING PARADOXES IN ECONOMIC EVALUATIONS (EES). AN EXAMPLE USING MOTOR NEURON DISEASE (MND) (page 157)

      Uk Bose, A Burrell and J Ward

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-239.x

    17. You have free access to this content
      ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN (page 157)

      A Szende, K Lovas, B Szebenyi, G Bàlint and G Héjj

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-238.x

    18. You have free access to this content
      COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY (pages 157–158)

      Jt Wang, Ce Barr, Y Torigoe, Ei Wang, Cr Rowland and Sd Goldfarb

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-240.x

    19. You have free access to this content
      MIGRAINE IN FRANCE IN 2000 : THERAPEUTICAL DATA (pages 158–159)

      C Lucas, M Lanteri-Minet, Jp Auray, G Duru, G Chazot, Jf Dartigues, P Henry, A Pradalier, A El Hasnaoui and Af Gaudin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-243.x

    20. You have free access to this content
    21. You have free access to this content
      COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMER'S DISEASE (page 158)

      S Niwata, Y Yamada and N Ikegami

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-241.x

    22. You have free access to this content
      SEE PPN5 (pages 159–160)

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-244.x

  43. Urinary & Kidney Disorders

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS (pages 160–161)

      Aj Boening, Mm Chapman, Rh Brown, Pg Zager and Kb Meyer

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-245.x

    2. You have free access to this content
      PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER (page 161)

      Z Zhou, Ce Barr, Y Torigoe and Te Williamson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-247.x

    3. You have free access to this content
      EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER (OAB) (page 161)

      Z Zhou, Ce Barr, Y Torigoe, Te Williamson and J Shah

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-246.x

    4. You have free access to this content
      ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION (pages 161–162)

      M Juzba, Tj White and Ey Chang

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-248.x

    5. You have free access to this content
      THE IMPACT OF PHARMACOTHERAPY ON OVERACTIVE BLADDER SYMPTOM IMPROVEMENT AND RESOURCE UTILIZATION (page 162)

      Cl Pashos, M Grossman and S Bull

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-249.x

    6. You have free access to this content
    7. You have free access to this content
      THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q) (page 162)

      K Coyne, P Abrams, D Revicki, R Herzog and T Hunt

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-250.x

    8. You have free access to this content
      THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS (pages 164–165)

      Aj Boening, Mm Chapman, Rh Brown, Pg Zager and Kb Meyer

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-252.x

  44. Women's & Men's Health

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      ERECTILE DYSFUNCTION: A PROSPECTIVE STUDY OF PATIENTS SEEKING THERAPY (pages 165–166)

      Se Jackson-Kline, Md Shepherd, Ec Divers, Ka Lawson, Kl Rascati and Rc Rosen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-255.x

    2. You have free access to this content
      A COST-MINIMIZATION ANALYSIS COMPARING MIRENA® WITH ORAL CONTRACEPTIVES (page 165)

      G Menard, M Pineau and S Laplante

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-254.x

    3. You have free access to this content
      PREMATURE BIRTH AND RESOURCE UTILIZATION IN A LARGE EMPLOYMENT BASED INDEPENDENT PRACTICE ASSOCIATION (IPA) (page 165)

      Cr Harley and S Leader

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-253.x

    4. You have free access to this content
      PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA (page 166)

      D Fielding, J Soon, M Levine and M Ensom

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-256.x

    5. You have free access to this content
    6. You have free access to this content
      HEALTH CARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH) (page 166)

      Ea Chrischilles, Lm Rubenstein, D Gilden and H Shah

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-257.x

    7. You have free access to this content
    8. You have free access to this content
      QUALITY OF LIFE IN POST-MENOPAUSAL WOMEN IN FIVE EUROPEAN COUNTRIES (pages 167–168)

      J Piercy, Y Zoellner, S Kay, L Abetz, J Alt and M Schaefer

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-260.x

  45. No Specific or Multiple Diseases-Health Policy

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST (page 168)

      Ss Sansgiry, Dj Hayes, Gk Rice, At Nadrash, Ke Erickson and Mu Bui

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-262.x

    2. You have free access to this content
      THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS: EXPERIENCES FROM SWEDEN (page 168)

      Ub Persson and A Anell

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-261.x

    3. You have free access to this content
      PHARMACOECONOMIC FELLOWSHIPS: STRUCTURE, PROCESS, AND OUTCOMES (pages 168–169)

      V Maio, Jh Lofland and Tk Girts

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-263.x

    4. You have free access to this content
      POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES (page 169)

      E Orlewska and P Mierzejewski

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-265.x

    5. You have free access to this content
      DEVELOPING A COMPREHENSIVE PERFORMANCE MEASUREMENT DATA SET FOR PHARMACEUTICAL BENEFIT MANAGEMENT PROGRAMS (page 169)

      Sr Long, Mh Hatzmann and Aj Chawla

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-264.x

    6. You have free access to this content
      ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS (pages 169–170)

      R Rotem, H Reuveni and A Goldberg

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-266.x

    7. You have free access to this content
      PRACTICE USE OF PHARMACOECONOMICS DATA IN HOSPITAL FORMULARY DECISIONS (pages 170–171)

      Ft Odedina, Jl Sullivan, R Nash and Cd Clemmons

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-268.x

    8. You have free access to this content
      APPLICATION OF HEALTH ECONOMICS IN THE CANADIAN PHARMACEUTICAL INDUSTRY (page 170)

      Z Hirji, De Rindress and Sa Welner

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-267.x

    9. You have free access to this content
      COMPARISON OF TECHNOLOGY ASSESSMENT IN LARGE MEDICAL GROUPS AND HEALTH MAINTENANCE ORGANIZATIONS (HMOS) (page 171)

      S Wise and Tf Donohue

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-269.x

    10. You have free access to this content
    11. You have free access to this content
    12. You have free access to this content
      COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION (pages 172–173)

      Jf Bussières and D Lebel

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-274.x

    13. You have free access to this content
      INDICES FOR EVALUATION OF DRUG COST/UTILIZATION: EVERY SILVER LINING HAS A GRAY CLOUD (page 172)

      Rj Valuck

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-273.x

    14. You have free access to this content
      ACUTE CARE ELDERLY UNITS: THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANTS (page 172)

      R Jayadevappa, Db Raziano, M Samakur and R Lavizzo-Mourey

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-272.x

    15. You have free access to this content
      THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISION MAKING (pages 173–174)

      L Morris and K Aikin

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-276.x

    16. You have free access to this content
    17. You have free access to this content
      A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA (page 174)

      Sm Walton, Ne Johnson, Bv Arondekar and Gt Schumock

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-278.x

    18. You have free access to this content
      PATIENT OUTCOMES IN THE SEDATED ICU PATIENT (page 174)

      T Kamath, A Hopefl, U Chaikledkaew and Ka Johnson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-277.x

    19. You have free access to this content
    20. You have free access to this content
      THE LAG BETWEEN EFFECTIVENESS AND COST-EFFECTIVENESS EVIDENCE OF NEW DRUGS AND DECISION-MAKING IN HEALTH CARE (page 175)

      Ba Stoykova, M Drummond and J Kleijnen

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-280.x

    21. You have free access to this content
      PATIENT ADHERENCE TO DRUG THERAPY IN A THREE-TIER COPAYMENT STRUCTURE (pages 175–176)

      S Hutchison

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-282.x

    22. You have free access to this content
      SINGLE EUROPEAN-LEVEL COST-EFFECTIVENESS ANALYSIS: OVER THE FOURTH HURDLE AND INTO THE DITCH? (page 175)

      J Hutton, M Nuijten and M Chambers

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-281.x

  46. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
  47. No Specific or Multiple Diseases-Health Policy

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DRUG REIMBURSEMENT PROGRAM FOR INDIGENT PATIENTS: AN ECONOMIC IMPACT ON THE HOSPTAL ADMINISTRATION BUDGET (page 176)

      Ab Nguyen, R Arbuckle, Rw Anderson and Ss Sansgiry

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-283.x

  48. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      CROSS-CULTURAL VARIATIONS IN SF-12 SCORES AMONG INDIVIDUALS WITH VARIOUS HEALTH CONDITIONS (pages 177–178)

      Sc Bolge, B Eschmann and Ja Donohue

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-287.x

    2. You have free access to this content
      DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE (page 177)

      Rd Crosby, Rl Kolotkin and Gr Williams

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-286.x

    3. You have free access to this content
      ROLE OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN THE EUROPEAN DRUG REGULATORY PROCESS: A REVIEW OF THE EMEA DOCUMENTS (page 177)

      C Acquadro, V Staniek and For The Eriqa Group

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-285.x

    4. You have free access to this content
      HEALTH UTILITIES INDEX MARK 3: AGREEMENT BETWEEN RATERS AND BETWEEN MODALITIES OF ADMINISTRATION (page 178)

      G Verrips, A Den Ouden, G Bonsel, R Gemke, N Paneth and S Verloove-Vanhorick

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-289.x

    5. You have free access to this content
      TRANSLATING SF-36 SCORES INTO PREFERENCES: AN EXAMINATION OF THE PERFORMANCE OF TWO PREDICTIVE EQUATIONS (page 178)

      Dm Meletiche, Cs Roberts and Jh Lofland

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-288.x

    6. You have free access to this content
      IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE? (pages 178–179)

      I Côté, Kb Farris and Dh Feeny

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-290.x

    7. You have free access to this content
      EVALUATING BIAS INTRODUCED BY ANNUALIZING UTILIZATION AND COST MEASURES (pages 179–180)

      M Zodet and G De Lissovoy

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-291.x

    8. You have free access to this content
      QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE (pages 180–181)

      Mf Botteman, Gm Pastores, Kf Gold, J Yeh, J Ali, W Aliski and Cl Pashos

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-292.x

    9. You have free access to this content
  49. No Specific or Multiple Diseases-Methodological Advances

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      METHODOLOGICAL ADVANCES IN THE ASSESSMENT OF QUALITY OF LIFE IN CLINICAL TRIALS (pages 181–182)

      Mr Hufford

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-295.x

  50. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE HEALTH AND WORK QUESTIONNAIRE (HWQ): AN INSTRUMENT FOR ASSESSING WORKPLACE PRODUCTIVITY IN RELATION TO WORKER HEALTH (page 181)

      R Shikiar, Am Rentz, Mt Halpern and Zm Khan

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-294.x

  51. No Specific or Multiple Diseases-Methodological Advances

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      DEVELOPMENT OF COST-EFFECTIVE WEB-BASED OUTCOMES RESEARCH STUDIES AND DISEASE MANAGEMENT PROGRAMS (page 182)

      Aj Ambegaonkar and D Day

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-296.x

    2. You have free access to this content
      DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT? (pages 182–183)

      La Faulkner, A Gafni and Bj O'Brien

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-297.x

    3. You have free access to this content
      A RISK ADJUSTMENT METHODOLOGY FOR CLAIMS DATA (page 183)

      P Wilson, Y Yuan and Bt Dowse

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-299.x

    4. You have free access to this content
      THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD: THE EIGHT CASES IN JAPAN (pages 183–184)

      I Kamae, S Yanagisawa and N Nakahara

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-300.x

    5. You have free access to this content
    6. You have free access to this content
      CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING (page 184)

      J Shi, J McCombs, J Hay, M Nichol, Cp Chou and C Hsiao

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-301.x

    7. You have free access to this content
      BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS: DOES IT MAKE A DIFFERENCE?? (pages 184–185)

      Bs Bloom

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-303.x

    8. You have free access to this content
      DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION (page 184)

      Dc Malone and Ma Raebel

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-302.x

    9. You have free access to this content
      COMPARISON OF STATISTICAL TESTS FOR THE COST/EFFECTIVENESS RATIOS (pages 185–186)

      S Kim, M Moeschberger and D Pathak

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-305.x

    10. You have free access to this content
      DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS (page 185)

      S Kim, M Moeschberger and D Pathak

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-304.x

    11. You have free access to this content
      BAYESIAN DECISION ANALYSIS IN OUTCOME STUDIES WITH SMALL NUMBERS OF EVENTS: A SIMULATION BASED PREDICTION APPROACH (pages 186–187)

      J Wang, P Davey and T MacDonald

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-308.x

    12. You have free access to this content
    13. You have free access to this content
    14. You have free access to this content
      CONDUCTING PHARMACOECONOMIC RESEARCH IN THE ABSENCE OF COUNTRY-SPECIFIC DATA (page 187)

      B Miller, Aj Rosner and Dl Becker

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-309.x

    15. You have free access to this content
      THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS): A NEW INSTRUMENT FOR MENTAL HEALTH SERVICES RESEARCH, RESULTS OF A FRENCH STUDY (pages 187–188)

      Jm Azorin, M Goudemand, M Toumi, S Johnson and Å Pettersson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-311.x

    16. You have free access to this content
      CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL (page 187)

      J Caro, M Salas, A Ward, J Sung and A Shah

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-310.x

    1. You have free access to this content
      Contributed Workshop Presentations (pages 188–195)

      Version of Record online: 1 MAY 2002 | DOI: 10.1046/j.1524-4733.2001.00203.x

  52. CONTRIBUTED WORKSHOP PRESENTATIONS

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      Issues And Problems Encountered In Models On Prevention Of Deep Venous Thrombosis (DVT) (pages 188–189)

      L Annemans, M Lamotte and M Huybrechts

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-3.x

    2. You have free access to this content
      A New Approach To Disease Modeling With Numerous Comparators And Multiple Decision Trees (pages 188–189)

      R Becker, L Noe, M Gore and S Martino

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-3a.x

    3. You have free access to this content
  53. No Specific or Multiple Diseases-Methodological Advances

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
      THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES (page 188)

      A Bakst, Dm Meletiche, R Arnold, H Harjono, M Najib and A Cobitz

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40202-312.x

  54. CONTRIBUTED WORKSHOP PRESENTATIONS

    1. Top of page
    2. ISPOR SIXTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PRESENTATION ABSTRACTS
    3. Economic Methodology Issues
    4. Economic Methodology Issues
    5. Medical Device & Diagnostics
    6. Economic Methodology Issues
    7. Medical Device & Diagnostics
    8. Quality of Life & Preference-based Measures
    9. Health Policy
    10. Quality of Life & Preference-based Measures
    11. Health Policy
    12. Cancer
    13. Health Policy
    14. Cancer
    15. Cardiovascular Disease
    16. Diabetes/Gastrointestinal Disorders
    17. Infectious Disease
    18. Diabetes/Gastrointestinal Disorders
    19. Infectious Disease
    20. Mental Health
    21. Musculoskeletal Disorders
    22. Mental Health
    23. Musculoskeletal Disorders
    24. Respiratory Disorders/Diseases
    25. Musculoskeletal Disorders
    26. Respiratory Disorders/Diseases
    27. Arthritis, Osteoporosis & Musculoskeletal Disorders
    28. Arthritis, Osteoporosis & Musculoskeletal Disorders
    29. Asthma & Respiratory Disorders
    30. Arthritis, Osteoporosis & Musculoskeletal Disorders
    31. Asthma & Respiratory Disorders
    32. Cancer
    33. Cardiovascular Disease
    34. Diabetes
    35. Cardiovascular Disease
    36. Diabetes
    37. Eye/Ear/Skin/Dental
    38. Diabetes
    39. Eye/Ear/Skin/Dental
    40. Gastrointestinal Disorders
    41. Infectious Diseases
    42. Mental Health
    43. Pain & Neurologic Disorders
    44. Urinary & Kidney Disorders
    45. Women's & Men's Health
    46. No Specific or Multiple Diseases-Health Policy
    47. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    48. No Specific or Multiple Diseases-Health Policy
    49. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    50. No Specific or Multiple Diseases-Methodological Advances
    51. No Specific or Multiple Diseases-Quality of Life & Preference-Based Measures
    52. No Specific or Multiple Diseases-Methodological Advances
    53. CONTRIBUTED WORKSHOP PRESENTATIONS
    54. No Specific or Multiple Diseases-Methodological Advances
    55. CONTRIBUTED WORKSHOP PRESENTATIONS
    1. You have free access to this content
    2. You have free access to this content
      CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA (pages 189–190)

      Mc Weinstein and S Appadoo

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-4.x

    3. You have free access to this content
    4. You have free access to this content
      BEYOND COST-EFFECTIVENESS: THE STRATEGIC VALUE OF PRODUCTIVITY-RELATED OUTCOMES IN CLINICAL TRIALS, BURDEN OF ILLNESS STUDIES, AND POST-MARKETING RESEARCH (page 190)

      Rj Ozminkowski, Rz Goetzel, Wc Crown, Sr Long and D Ling

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-6.x

    5. You have free access to this content
      CONDUCTING COST-BENEFIT AND COST-UTILITY ANALYSES: A CONJOINT ANALYSIS APPROACH (page 190)

      Ab Hauber, Mv Bala and Se Fehnel

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-5.x

    6. You have free access to this content
      THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING (page 191)

      Gp Hess and E Forman

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-8.x

    7. You have free access to this content
      MULTINATIONAL ECONOMIC STUDIES: LESSONS LEARNED FROM TRIAL-BASED AND MODELLING STUDIES (pages 191–192)

      Mf Drummond and D Grima

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-9.x

    8. You have free access to this content
      CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH (pages 192–193)

      Cd Mullins, S Weiss and T Fulda

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-12.x

    9. You have free access to this content
      USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES (page 192)

      Ja Cramer and J Urquhart

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-11.x

    10. You have free access to this content
      USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS: AN ILLUSTRATION (page 192)

      Mv Bala and Ja Mauskopf

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-10.x

    11. You have free access to this content
    12. You have free access to this content
      MAKING MODELS BETTER (page 193)

      Db Matchar, Gp Samsa and G Parmigiani

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-13.x

    13. You have free access to this content
      SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES: FIRST PRINCIPLES (page 194)

      P Erickson

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-16.x

    14. You have free access to this content
      PATIENT REGISTRIES: THEIR VALUE IN OUTCOMES RESEARCH (page 194)

      Mw Russell

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-15.x

    15. You have free access to this content
      THE ROLE OF HEALTH STATE EXPERIENCE IN LONGITUDINAL CONJOINT ANALYSIS OF PATIENT PREFERENCES (pages 194–195)

      M Bingham and G Smith

      Version of Record online: 9 OCT 2008 | DOI: 10.1046/j.1524-4733.2001.40203-17.x

SEARCH

SEARCH BY CITATION